ixi is a biotech company focused on multidisciplinary innovation in stem cells and genome editing, with a stated aim of advancing regenerative medicine and preventive healthcare. Its stated vision is to become a global leader in regenerative medicine, delivering science-driven solutions that extend human healthspan and enhance wellness. The company states that it operates under Good Manufacturing Practice (GMP) standards, uses ethically sourced biological materials, and aligns with international regulatory frameworks, with Environmental, Social, and Governance principles intended to guide its long-term strategy.

The company's product range consists of cell and exosome materials for research and therapeutic applications. hMSCs are mesenchymal stem cells derived from Wharton's jelly, marketed for tissue engineering, inflammation modulation and cellular therapy research. hHSCs are hematopoietic stem cells from umbilical cord blood, marketed for hematopoiesis research, immune system studies and gene therapy. ExoCell is an exosome preparation isolated by ultracentrifugation from the serum-free media of Wharton's jelly-derived hMSCs, marketed for regenerative medicine and cellular communication studies. Listed specifications include 2 ml vials stored between -196°C and -80°C, with a stated count of 10 million cells per vial and viability above 80%.

The company is based at Novum Labs at the Karolinska Institutet campus in Huddinge, Sweden. LinkedIn lists a team of about one employee. No funding rounds, news coverage or related companies were found in the available sources.